| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/29/2007 | EP1824957A2 Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1 |
| 08/29/2007 | EP1824515A2 Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations |
| 08/29/2007 | EP1824498A2 Methods and compositions for treating cellular proliferative diseases |
| 08/29/2007 | EP1648476B1 Mouth and/or throat wash |
| 08/29/2007 | EP1450847A4 Apo2 ligand/trail formulations |
| 08/29/2007 | EP1450813B1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of menorrhagia |
| 08/29/2007 | EP1306083A4 Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion |
| 08/29/2007 | EP1236046B1 Methods for screening compounds active on neurons |
| 08/29/2007 | EP1096932B1 Antihypertensive combination of valsartan and calcium channel blocker |
| 08/29/2007 | EP1024814B1 Use of antifungal agents for the topical treatment of fungus-induced mucositis |
| 08/29/2007 | EP0998585B1 Screening methods using an atpase protein from a virus of the flaviviridae family |
| 08/29/2007 | EP0983086B1 pH-SENSITIVE LIPOSOMES AND OTHER TYPES OF ENCAPSULATED VACCINES CONTAINING IMMUNOMODULATORS, AND METHODS FOR MAKING AND USING SAME |
| 08/29/2007 | CN101027560A Human G protein-coupled receptor for the treatment of hyperglycemia and related disorders and its modulator |
| 08/29/2007 | CN101027086A Use of targeted oxidative therapeutic formulation in bone regeneration |
| 08/29/2007 | CN101027065A Phospholipid compositions and methods for their preparation and use |
| 08/29/2007 | CN101027064A Medicinal composition containing diabetes therapeutic agent |
| 08/29/2007 | CN101027061A Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| 08/29/2007 | CN101027048A Medicinal composition as immunosuppressant |
| 08/29/2007 | CN101024671A 丙型肝炎病毒抑制剂 Hepatitis C virus inhibitors |
| 08/29/2007 | CN101024083A Medicine for treating gustric disease |
| 08/29/2007 | CN101024082A Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof |
| 08/29/2007 | CN101023946A Use of EP4 receptor ligands in the treatment of IL-6 involved diseases |
| 08/29/2007 | CN101023932A Coated granules containing ibuprofen |
| 08/29/2007 | CN101023931A Anti-cancer composition containing blood-vessel inhibitor and taxanes |
| 08/29/2007 | CN101023930A Anti-cancer composition carried with new-born blood-vessel inhibiting agent and alkalating agent |
| 08/29/2007 | CN101023929A Anti-cancer medicine composition carried with blood-vessel inhibiting agent and synergistic agent |
| 08/29/2007 | CN101023928A Slow-release injecta containing new-born blood-vessel-inhibiting agent and platinum-like compounds |
| 08/29/2007 | CN101023925A Anti-cancer composition containing chemical-therapy synergistic agent |
| 08/29/2007 | CN101023924A Entity-tumor-resistant slow-release agent containing glucocorticoid hormone |
| 08/29/2007 | CN101023923A Anti-cancer slow-release agent containing glucocorticoid hormone |
| 08/29/2007 | CN101023922A Anti-cancer slow-release agent carried with glucocorticoid hormone and chemical therapy medicine |
| 08/29/2007 | CN101023921A Anti-cancer composition containing glucocorticoid hormone |
| 08/29/2007 | CN101023920A Entity-tumor-resistant medicine composition |
| 08/29/2007 | CN101023919A Entity-tumor-resistant slow-release agent |
| 08/29/2007 | CN101023918A Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone |
| 08/29/2007 | CN101023893A Endoluminal device for treating disease of aneurysm and combination of drugs |
| 08/28/2007 | US7262286 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 08/28/2007 | US7262199 Tyrosine kinase inhibitors |
| 08/28/2007 | US7262187 Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor |
| 08/28/2007 | US7262186 Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl0-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-dihydro-1N-pyrrol-1-carboxamide |
| 08/28/2007 | US7262173 Chemosensitizing with liposomes containing oligonucleotides |
| 08/28/2007 | US7262044 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 08/28/2007 | US7262005 Methods of protein destabilization and uses thereof |
| 08/28/2007 | US7261905 Disinfectant and method of making |
| 08/28/2007 | US7261889 Local anesthetic methods and kits |
| 08/28/2007 | US7261881 Providing an agent capable of inducing a leptin or leptin receptor-mediated angiogenic response; and administering to a subject in need of wound healing, an effective amount of the agent to promote wound healing, wherein the agent is leptin |
| 08/28/2007 | US7261880 Methods of treating Syndrome X with aliphatic polyamines |
| 08/28/2007 | US7261735 Local drug delivery devices and methods for maintaining the drug coatings thereon |
| 08/28/2007 | CA2485337C Analgesic composition and method |
| 08/28/2007 | CA2405072C Gel compositions containing metronidazole |
| 08/28/2007 | CA2367755C Dimeric compounds and their use as inhibitors of neuraminidase |
| 08/28/2007 | CA2218619C Antibacterial-wound healing compositions and methods for preparing and using same |
| 08/28/2007 | CA2184727C Proteasome regulation of nf-kb activity |
| 08/23/2007 | WO2007095583A2 Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin |
| 08/23/2007 | WO2007094495A2 Novel anticancer cathepsin preparation and anticancer agent for combination therapy against cancer using the same |
| 08/23/2007 | WO2007093635A2 Proteasom or ups inhibitor for treating infections with influenza viruses |
| 08/23/2007 | WO2007093624A2 Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
| 08/23/2007 | WO2007093587A1 Use of r-(-)-2,4-diamino-5-(2, 3-dichlorophenyl)-6-fluoromethyl pyrimidine for the treatment of psychotic disorders |
| 08/23/2007 | WO2007093183A2 Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases |
| 08/23/2007 | WO2007093027A1 Delayed release pharmaceutical oral dosage form and method of making same |
| 08/23/2007 | WO2007093021A1 Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, angina and others kinds of cardiovascular diseases. |
| 08/23/2007 | WO2007069272A3 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| 08/23/2007 | WO2007067795A3 Methods for identifying and targeting tumor stem cells based on nuclear morphology |
| 08/23/2007 | WO2007039058A3 Use of opioid receptor antagonists |
| 08/23/2007 | WO2007011960A3 Methods and agents to treat autoimmune diseases |
| 08/23/2007 | WO2006120568A3 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone |
| 08/23/2007 | WO2006120567A3 Pharmaceutical composition comprising an anti-bacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol |
| 08/23/2007 | WO2006120565A3 Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol, carvacrol and alpha- and beta-ionones |
| 08/23/2007 | WO2006113485A3 Aminergic pharmaceutical compositions and methods |
| 08/23/2007 | WO2005123907A3 Ex-vivo application of solid microparticulate therapeutic agents |
| 08/23/2007 | WO2005089738A3 Use and administration of bacterial efflux pump inhibitors |
| 08/23/2007 | WO2002097035A3 Secreted proteins |
| 08/23/2007 | US20070199080 Diagnostic and therapeutic use of F-box proteins for Alzheimer's disease and related neurodegenerative disorders |
| 08/23/2007 | US20070197954 Medical devices with enhanced ultrasonic visibilty |
| 08/23/2007 | US20070197666 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 08/23/2007 | US20070197662 Amine compounds and inhibiting neurotransmitter reuptake |
| 08/23/2007 | US20070197654 Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease |
| 08/23/2007 | US20070197602 Combined pharmaceutical composition |
| 08/23/2007 | US20070197580 To treat irritable bowel syndrome; side effect reduction, improved pharmacodynamics and safety, more potent and selective; 2-imidazomethyl- pyrido(4,3-b)indol-1-one or -carbazol-1-one derivatives containing an ester group |
| 08/23/2007 | US20070197562 Remedies for prostatic hypertrophy |
| 08/23/2007 | US20070197560 cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction |
| 08/23/2007 | US20070197551 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome |
| 08/23/2007 | US20070197547 4-(1-piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 4-(1-piperazinyl)-1-methyl-3-nitro-2(1H)-quinolone |
| 08/23/2007 | US20070197544 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| 08/23/2007 | US20070197543 Use of derivatives of 2, 5-dihydroxyb enzene-sulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile dysfunction |
| 08/23/2007 | US20070197471 Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors |
| 08/23/2007 | US20070197462 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus (EBV) or Kaposi's sarcoma-associated herpes (KHSV) |
| 08/23/2007 | US20070197456 Preparation and diabetic use of Gibberellins |
| 08/23/2007 | US20070197450 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| 08/23/2007 | US20070197434 Theurapeutic or prophyiactic agent for arthritis |
| 08/23/2007 | US20070197425 comprising a thiazolidinedione, one or more of chromium picolinate or chromium polynicotinate; bioavailable source of vanadium is vanadyl sulfate; synergistic mixture |
| 08/23/2007 | US20070196931 selectively kill Fusobacterium varium cells, or neutralize the toxin produced by Fusobacterium varium cells; differential diagnosis between ulcerative colitis and inflammatory bowel disease |
| 08/23/2007 | US20070196883 Enzyme |
| 08/23/2007 | US20070196512 Combinations of vanadium with antidiabetics for glucose metabolism disorders |
| 08/23/2007 | US20070196467 Indium supplement compositions and methods therefor |
| 08/23/2007 | US20070196445 Method for the Prevention and Treatment of Cachexia and Anorexia |
| 08/23/2007 | US20070196433 Methods and devices for the sustained release of multiple drugs |
| 08/23/2007 | US20070196390 Equine herpesvirus vaccine |
| 08/23/2007 | US20070196377 polynucleotide; rho genes rho proteins; guanosine triphosphate binding proteins; antibody against the protein encodes polynucleotide; detection and treating stomach tumor; determining a disease, a pharmaceutical composition, and a reagent kit |
| 08/23/2007 | US20070196370 Type 2 cytokine receptor and nucleic acids encoding same |